- Education
-
Research
Current research
Talent
-
Collaboration
Businesses
Government agencies and institutions
Alumni
-
About AU
Organisation
Job at AU
Professor Lars Dyrskjøt Andersen and Professor Jørgen Bjerggaard from Aarhus University and Aarhus University Hospital receive DKK 15 million from The Novo Nordisk Foundation. The grant will be used to develop methods that can predict the right treatment for patients with bladder cancer.
2017.04.06 |
Lars Dyrskjødt Andersen receive DKK 15 from The Novo Nordisk Foundation for research into bladder cancer. Photo: private.
Patients suffering from cancer of the bladder where the cancer has spread to other parts of the body currently receive chemotherapy and will in future also be able to receive immunotherapy. Unfortunately, a proportion of the patients either fail to benefit or only benefit a little from the treatments, and it is not possible to predict the effect of the two types of treatments.
The grant from The Novo Nordisk Foundation will be used to develop and implement new, precise molecular methods to identify the patients with bladder cancer who will benefit most from chemotherapy and immunotherapy. By studying the different cancer cells and their interactions with the immune cells, the goal of the researchers is to develop biomarker models that can predict the response to the treatments, thus making it possible to tailor treatment to the individual patient and ultimately increase the patient's chances of survival.
Professor Lars Dyrskjøt Andersen
Aarhus University, Department of Clinical Medicine and
Aarhus University Hospital, Department of Molecular Medicine
Direct tel.: (+45) 7845 5320
Email: lars@clin.au.dk